Hologic, Inc. (NASDAQ:HOLX) Holdings Cut by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ lowered its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 35.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 210,664 shares of the medical equipment provider’s stock after selling 118,100 shares during the quarter. Skandinaviska Enskilda Banken AB publ owned about 0.09% of Hologic worth $15,223,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of HOLX. Swedbank AB raised its holdings in shares of Hologic by 18.8% during the 3rd quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock valued at $157,788,000 after purchasing an additional 306,562 shares in the last quarter. Principal Financial Group Inc. raised its holdings in shares of Hologic by 3.6% during the 3rd quarter. Principal Financial Group Inc. now owns 269,546 shares of the medical equipment provider’s stock valued at $21,957,000 after purchasing an additional 9,419 shares in the last quarter. Assetmark Inc. raised its holdings in shares of Hologic by 27.5% during the 3rd quarter. Assetmark Inc. now owns 6,667 shares of the medical equipment provider’s stock valued at $543,000 after purchasing an additional 1,437 shares in the last quarter. Covestor Ltd raised its holdings in shares of Hologic by 23.8% during the 3rd quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock valued at $56,000 after purchasing an additional 133 shares in the last quarter. Finally, Crossmark Global Holdings Inc. raised its holdings in shares of Hologic by 2.2% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 18,101 shares of the medical equipment provider’s stock valued at $1,474,000 after purchasing an additional 393 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Stock Performance

NASDAQ HOLX opened at $60.70 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The company’s fifty day moving average is $67.65 and its two-hundred day moving average is $74.94. Hologic, Inc. has a 52-week low of $60.33 and a 52-week high of $84.67. The firm has a market capitalization of $13.62 billion, a price-to-earnings ratio of 19.15, a P/E/G ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Equities research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on HOLX shares. Jefferies Financial Group started coverage on shares of Hologic in a report on Tuesday, December 10th. They set a “hold” rating and a $85.00 price target on the stock. Evercore ISI dropped their target price on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating on the stock in a report on Thursday, February 6th. Wolfe Research started coverage on shares of Hologic in a report on Friday, December 13th. They issued a “peer perform” rating on the stock. Argus downgraded shares of Hologic from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Finally, Leerink Partnrs downgraded shares of Hologic from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.